News

Given a general rise in STD cases, clinicians treating ESRD may have to pay special attention to possible coinfections.

Eravacycline may be an option for patients with a history of C diff or those with a history of infections who are at risk for developing the infection.

Pooled analysis linked baseline demographics, including lower CD4 count, higher HIV-1 RNA, no history of injection drug use, female sex, and black race, to weight gain following ART initiation.

The ECDC 2019 plan to address multi- and extensively-drug resistant gonorrhea has been released.

Here is a look at infectious disease-related US Food and Drug Administration (FDA) news from the week of October 13, 2019.

We’ve rounded up a list of important US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) recalls from this past week.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Angela Campbell, MD, MPH, details a study on influenza vaccine effectiveness in children with respiratory illness.

Dissemination of fungi, including Cryptococcus neoformans and Candida albicans, is limited by liver macrophages, according to a new study from the University of Maryland.

The latest report from the CDC shows that preventable infections are on the rise nationally. Particularly hard hit are women, young people, minority groups, and infants exposed to syphilis.

Although the overall mortality rate for HCV has declined, clinicians will have to focus on individuated factors to address lingering barriers.

The approval marks the first and only antiviral medicine indicated specifically for patients at high risk of developing serious complications from the flu.

While infectious disease consultations reduced the amount of antibiotics used for patients, it only affected C diff rates at 1 of 3 hospitals in the study.

The committee voted 14 to 2 that substantial evidence of efficacy and safety for cefiderocol was provided for the treatment of cUTI including pyelonephritis in patients with limited or no alternative treatment options.

A patient was evaluated for Ebola in a Swedish hospital. Here's what we should take away from it.

Paul Abrams, MBA, director of Health Care Specialty Group at MJH Life Sciences, spoke to Vaibhav Singh from Circle of Life about Zevac, a tool that aims to help clinicians make more informed prescribing decisions.

NEJM study suggests testing everyone, regardless of symptoms, can reduce prevalence.

Samuel L. Aitken, PharmD, MPH, shares the lessons learned from a case study on a patient with Stenotrophomonas maltophilia infection.

A study suggests young black MSM can experience delays in PrEP initiation if they do not have health insurance, even if expanded access through manufacturer assistance programs is offered.

Elizabeth Hirsch, PharmD, and Delaney Hart, PharmD, discuss their poster at IDWeek 2019.

Millions of women and infants remain vulnerable to influenza and pertussis despite recommendations for vaccinations in pregnancy, according to a CDC report.

Deanna Buehrle, PharmD, discusses her study on bloodstream infections in solid organ transplant recipients.

The study focused on women living with HIV in areas where TB is highly prevalent.

Evaluating the impact of the 2016 FDA boxed warning on fluoroquinolone prescribing rates for uncomplicated urinary tract infections.

Candidemia is the fourth most common health care-associated infection. To improve hospitalized patients’ safety, infectious disease physicians should be consulted.

Here is a look at infectious disease-related US Food and Drug Administration (FDA) news from the week of October 6, 2019.

We’ve rounded up a list of important US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) recalls from this past week.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Keith S. Kaye, MD, MPH, discusses the current treatment landscape for pneumonia in the ICU setting, and previews the topline results of the phase 3 RESTORE-IMI 2 trial.

Reported hepatitis A vaccinations consistently fell below potentially achievable coverage between 2008 and 2017, highlighting the need for to improve simultaneous administration of childhood vaccines, according to the CDC.